Meet the Proteona team at the CAR-TCR Sumit Asia in Shanghai, China
Innovative combined genomic and proteomic analysis platform for Immuno-Oncology and Single Cell BioMedical Applications
The Proteona team will attend the CAR-TCR Summit Asia from the 19th to the 20th June 2019, taking place in Shanghai, China. The CAR-TCR Summit Asia focusses on clinical application of cell immunotherapies, especially CAR T and TCR therapies. It covers important topics such as new technologies to improve CAR T manufacturing process.
The team will be available during the conference to share about the new ESCAPETM CAR T platform. This new product will be available for comprehensive characterization of CAR T immunotherapeutics, and can be integrated into all stages of CAR T therapy from quality control to analysing patient follow-up samples.
For media queries, please contact:
Dr Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).